The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and ...

Global Prefilled Syringes Market was valued at US$ 1,432.2 million in 2020 and is anticipated to reach US$ 3,301.1 million by 2027 displaying an elevated CAGR of 10% over the forecast period ...

The available dosages include 45 mg/0.5 mL prefilled syringe, 90 mg/mL prefilled syringe, 45 mg/0.5 mL vial, and 130 mg/26 mL vial. The US Food and Drug Administration (FDA) approved Yesintek in ...

3D screen printing provides innovative drug development capabilities that are difficult or impossible to achieve with traditional methods, including complex multi-layered formulations, precision ...

Download this white paper and discover how Stevanato Group's innovative syringe platform answers this challenge.

Healthcare Packaging Editor-in-Chief Liz Cuneo talks with founder of SOLUtion Medical, Julia Anthony, about how their prefilled syringe reduces preparation steps. May 2, 2025 Follow this podcast on ...

Moreover, in April 2025, Regeneron's US supplementary application for Eylea HD's prefilled syringe was rejected; this packaging format is important for the product's competitiveness with Vabysmo ...

However, the regulatory body issued a complete response letter (CRL) for the Eylea HD pre-filled syringe ... some time now due to competition from Vabysmo. We note that Vabysmo's uptake has ...

Roche's Vabysmo sales reached 1.02 billion Swiss ... the FDA last week rejected the company’s application for a prefilled syringe version of Eylea HD. Just days before that complete response ...

Eylea’s sales in the United States plunged 39% year over year to $736 million, primarily due to increased competition from other drugs like Roche’s RHHBY Vabysmo, loss in market share to ...

Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye disease drug Eylea, sending the company's shares tumbling 7% in premarket ...

Regeneron Pharmaceuticals (REGN) reported its first-quarter 2025 earnings, revealing a miss on both earnings and revenue expectations. The company posted earnings per share (EPS) of $8.22, falling ...